GW&K Investment Management’s SpringWorks Therapeutics SWTX Stock Holding History

GW&K Investment Management’s Portfolio SWTX Stock Details SWTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q3	–	Sell	-4,478	Closed	-$210K	–	1012
2025 Q2	$210K	Sell	4,478 -864,464	-99%	-$38.5M	﹤0.01%	376
2025 Q1	$38.3M	Sell	868,942 -105,443	-11%	-$4.85M	0.36%	110
2024 Q4	$35.2M	Buy	974,385 +49,024	+5%	+$1.71M	0.3%	132
2024 Q3	$29.6M	Buy	925,361 +241,822	+35%	+$9.04M	0.25%	161
2024 Q2	$25.7M	Buy	683,539 +573,944	+524%	+$24.2M	0.24%	167
2024 Q1	$5.39M	Buy	+109,595	New	+$5.07M	0.05%	271

Other funds holding SWTX

DekaBank Deutsche Girozentrale Frankfurt, Germany $60.6B AUM 23.27% 1-Year Est. Return

Osaic Holdings Scottsdale, Arizona $68.3B AUM 20.5% 1-Year Est. Return

HNB

Huntington National Bank Columbus, Ohio $18.1B AUM 24.69% 1-Year Est. Return

GW&K Investment Management's SWTX Position: Q3 2025 in Review

GW&K Investment Management sold out of SpringWorks Therapeutics (SWTX) in Q3 2025, closing a stake of 4,478 shares — an estimated $210K sold.

GW&K Investment Management first reported a position in SWTX in Q1 2024 and held it in 6 quarters. The position peaked at $38.3M in Q1 2025. 3 funds tracked by Wall St. Rank hold SWTX as of Q3 2025.

GW&K Investment Management reported no remaining SpringWorks Therapeutics position as of Q3 2025 after selling out during the quarter.
GW&K Investment Management sold 4,478 SpringWorks Therapeutics shares in Q3 2025, an estimated $210K.
GW&K Investment Management first reported a position in SpringWorks Therapeutics in Q1 2024 and held it in 6 quarters.
GW&K Investment Management's SpringWorks Therapeutics position peaked at $38.3M in Q1 2025.
3 funds tracked by Wall St. Rank held SpringWorks Therapeutics as of Q3 2025.

Based on GW&K Investment Management's 13F filing for Q3 2025, filed 12 Nov 2025.